EMA Recommends Approval of 10 Drugs
The agency recommended approval of 11 drugs, including three cancer drugs, in September.
Updated 9/21/16
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of 10 drugs during their Sept. 12–15, 2016 meeting. The approved drugs treat a range of conditions including different forms of cancer, type 2 diabetes, secondary hyperparathyroidism, heart failure, and HIV.
CHMP recommended the following:
- Conditional marketing authorization was given to Lartruvo, for the treatment of adults with advanced soft tissue sarcoma.
- Marketing authorization for Ibrance, for the treatment of locally advanced or metastatic breast cancer.
- Conditional marketing authorization for Ninlaro (ixazomib) for the treatment of multiple myeloma.
- Approval of Glyxambi (empagliflozin/linagliptin) for the treatment of type 2 diabetes.
- Approval of Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism.
- Positive opinion for Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid) for the treatment of cerebrotendinous xanthomatosis.
CHMP also recommended the approval of four generic drugs: Ivabradine JensenR (ivabradine) and Ivabradine Zentiva (ivabradine) to treat angina pectoris and heart failure, Emtricitabine/ Tenofovir disoproxil Zentiva (emtricitabine/tenofovir disoproxil) to treat HIV infection, and Granpidam (sildenafil) for the treatment of patients with pulmonary arterial hypertension.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
